Neko Health Raises $700 Million to Bring AI-Powered Body Scans to the United States

Neko Health, a company specializing in AI-driven preventive healthcare, has secured an impressive $700 million in funding, according to AI News Health. The capital will be used to expand the company's operations into the United States, with the first concrete step being the opening of a clinic in New York City.

A Funding Round Led by Heavyweight Venture Capital Names

The Series C round was led by Lightspeed Venture Partners, one of Silicon Valley's most influential investment firms, with O.G. Venture Partners serving as co-lead, according to AI News Health. Existing investors also participated in the round, signaling continued confidence in the company's business model. The raise places Neko Health among the best-funded startups in the global digital health space.

What Neko Health's Screening Service Offers

Neko Health's approach sets it apart from traditional medical services through an integrated, prevention-first model. According to AI News Health, the company's platform combines multiple technologies and medical assessment methods into a single examination workflow: advanced medical imaging, blood tests, proprietary in-house developed sensors, and specialist physician review of results.

The company's stated goal is to detect health issues before they become critical, giving patients a comprehensive picture of their physical condition. This preventive medicine philosophy is gaining increasing traction among both investors and the public, particularly as traditional healthcare systems face mounting pressure.

The U.S. Expansion: A Major Test

The choice of New York City as the entry point into the American market is no coincidence. The city represents one of the most competitive and demanding environments for private medical services, and success in this metropolis could open the door to other major U.S. cities.

Neko Health was founded in Sweden and built a solid reputation across Europe before setting its sights on transatlantic expansion. Its model — which places artificial intelligence at the heart of the preventive diagnostic process — reflects a growing trend in the global healthcare industry, where data and algorithms are increasingly complementing, and in some cases anticipating, human clinical judgment.

How this service will be received in a market as complex as the United States — where healthcare regulations are strict and competition among private medical providers is fierce — remains to be seen.